{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:41:43Z","timestamp":1787506903258,"version":"build-2736575974"},"reference-count":77,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Neck disability and pain are frequently encountered problems in patients with chronic migraine (CM). The long-term stimuli of neurons in the trigeminocervical junction may explain this situation. OnabotulinumtoxinA (ONA) treatment is one of the proven treatments for CM; however, there is no study data on the efficacy of ONA treatment on neck disability and pain in CM patients. Therefore, we aimed to investigate the effect of ONA treatment on disability, neck pain and headache intensity in CM patients. One hundred thirty-four patients who met the inclusion criteria were included in the study. ONA treatment was administered at a dose of 195 U to 39 sites in total as per Follow-the-Pain PREEMPT protocol. The disability was evaluated with the Neck Disability Index and the Migraine Disability Assessment; pain intensity was evaluated with the Visual Analogue Scale; the monthly number of headache days were recorded; quality of life was evaluated with the Headache Impact Test. All assessments were recorded at baseline and 3 months after treatment. After the treatment, neck\u2013migraine disabilities decreased from severe to mild for neck and moderate for migraine (p &lt; 0.001). Neck pain and headache intensities decreased by almost half (p &lt; 0.001). The median number of monthly headache days decreased from 20 days to 6 days (p &lt; 0.000). The quality-of-life level decreased significantly from severe to substantial level (p &lt; 0.001). According to our results, ONA treatment was effective in reducing neck-related problems in CM patients. Long-term follow-up results may provide researchers with more comprehensive results in terms of the treatment of chronic migraine\u2013neck-related problems.<\/jats:p>","DOI":"10.3390\/toxins15010029","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T03:00:59Z","timestamp":1672628459000},"page":"29","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-6135","authenticated-orcid":false,"given":"Dilara","family":"Onan","sequence":"first","affiliation":[{"name":"Spine Health Unit, Faculty of Physical Therapy and Rehabilitation, Hacettepe University, Ankara 06230, T\u00fcrkiye"},{"name":"Department of Clinical and Molecular Medicine, Sapienza University, 000189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-9905","authenticated-orcid":false,"given":"Enrico","family":"Bentivegna","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University, 000189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-4128","authenticated-orcid":false,"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University, 000189 Rome, Italy"},{"name":"Regional Referral Headache Centre, Sant\u2019Andrea Hospital, 000189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","article-title":"The global prevalence of headache: An update, with analysis of the influences of methodological factors on prevalence estimates","volume":"23","author":"Stovner","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s10194-022-01471-3","article-title":"Applying a biopsychosocial model to migraine: Rationale and clinical implications","volume":"23","author":"Rosignoli","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jmpt.2018.04.003","article-title":"Relationship between headaches and neck pain characteristics with neck muscle strength","volume":"41","author":"Tolentino","year":"2018","journal-title":"J. Manip. Physiol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1526-4610.2012.02155.x","article-title":"Self-reported comorbid pains in severe headaches or migraines in a US national sample","volume":"52","author":"Plesh","year":"2012","journal-title":"Headache"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/head.12393","article-title":"Neck pain disability is related to the frequency of migraine attacks: A cross-sectional study","volume":"54","author":"Florencio","year":"2014","journal-title":"Headache"},{"key":"ref_6","unstructured":"(2016, April 08). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/headache-disorders."},{"key":"ref_7","unstructured":"(2022, July 14). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/musculoskeletal-conditions."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/03331024211068073","article-title":"Prevalence of neck pain in migraine: A systematic review and meta-analysis","volume":"42","author":"Younis","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s10194-015-0566-9","article-title":"Neck pain in episodic migraine: Premonitory symptom or part of the attack?","volume":"16","author":"Lampl","year":"2015","journal-title":"J. Headache Pain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1468-2982.2002.00293.x","article-title":"Occipital headaches stemming from the lateral atlanto-axial (C1\u20132) joint","volume":"22","author":"Aprill","year":"2002","journal-title":"Cephalalgia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s10194-022-01525-6","article-title":"Tracking the evolution of non-headache symptoms through the migraine attack","volume":"23","author":"Messina","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1526-4610.2005.4501003.x","article-title":"Migraine pathophysiology","volume":"45","author":"Goadsby","year":"2005","journal-title":"Headache"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11916-005-0061-0","article-title":"Migraine and the neck: New insights from basic data","volume":"9","author":"Bartsch","year":"2005","journal-title":"Curr. Pain Head Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00007632-199807010-00001","article-title":"Extracranial nerves in the posterior part of the head: Anatomic variations and their possible clinical significance","volume":"23","author":"Becser","year":"1998","journal-title":"Spine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/brain\/awg190","article-title":"Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater","volume":"126","author":"Bartsch","year":"2003","journal-title":"Brain"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1177\/0333102419854061","article-title":"Is the presence of neck pain associated with more severe clinical presentation in patients with migraine? A cross-sectional study","volume":"39","author":"Bragatto","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bjpt.2019.01.001","article-title":"Reduced flexion rotation test in women with chronic and episodic migraine","volume":"23","author":"Florencio","year":"2019","journal-title":"Braz. J. Phys. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Pinheiro, C.F., Oliveira, A.S., Will-Lemos, T., Florencio, L.L., Fern\u00e1ndez-de-Las-Pe\u00f1as, C., Dach, F., and Bevilaqua-Grossi, D. (2021). Neck Active Movements Assessment in Women with Episodic and Chronic Migraine. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173805"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40945-021-00123-0","article-title":"Cervical musculoskeletal impairments in migraine","volume":"11","author":"Liang","year":"2021","journal-title":"Arch. Physiother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15434","DOI":"10.1038\/s41598-021-95078-4","article-title":"Comparison of cervical muscle isometric force between migraine subgroups or migraine-associated neck pain: A controlled study","volume":"11","author":"Florencio","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1590\/S1413-35552012005000137","article-title":"Body posture changes in women with migraine with and without temporomandibular disorders","volume":"18","author":"Ferreira","year":"2014","journal-title":"Braz. J. Phys. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1097\/01.brs.0000141170.89317.0e","article-title":"Patients with neck pain demonstrate reduced electromyographic activity of the deep cervical flexor muscles during performance of the craniocervical flexion test","volume":"29","author":"Falla","year":"2004","journal-title":"Spine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/2049463720924704","article-title":"Involvement of cervical disability in migraine: A literature review","volume":"15","author":"Aoyama","year":"2021","journal-title":"Br. J. Pain"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_26","unstructured":"(2012, June 27). NICE Technology Appraisal Guidance 260 (2012) Botulinum Toxin Type A for the Prevention of Headaches in Adults with Chronic Migraine. Available online: https:\/\/www.nice.org.uk\/guidance\/ta260."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","article-title":"Guideline on the use of onabotulinumtoxinA in chronic migraine: A consensus statement from the European Headache Federation","volume":"19","author":"Bendtsen","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14737175.2020.1825077","article-title":"What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group","volume":"20","author":"Sacco","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of injection of onabotulinumtoxinA for chronic migraine: A safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program","volume":"50","author":"Blumenfeld","year":"2010","journal-title":"Headache"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pain.2008.10.005","article-title":"Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin","volume":"141","author":"Gazerani","year":"2009","journal-title":"Pain"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1242\/jcs.012211","article-title":"Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential","volume":"120","author":"Meng","year":"2007","journal-title":"J. Cell Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pain.2006.04.014","article-title":"The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization","volume":"122","author":"Gazerani","year":"2006","journal-title":"Pain"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","article-title":"Subcutaneous administration of botulinum toxin A reduces formalin-induced pain","volume":"107","author":"Cui","year":"2004","journal-title":"Pain"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy","volume":"44","author":"Durham","year":"2004","journal-title":"Headache"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0041-0101(99)00153-1","article-title":"Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins","volume":"38","author":"Welch","year":"2000","journal-title":"Toxicon"},{"key":"ref_36","first-page":"S36","article-title":"Botulinum Toxin in Migraine Treatment","volume":"50","author":"Aydinlar","year":"2013","journal-title":"N\u00f6ropsikiyatri Ar\u015fivi"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s10194-020-01157-8","article-title":"Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA","volume":"21","author":"Gallardo","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s10072-016-2665-z","article-title":"Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine","volume":"37","author":"Demiryurek","year":"2016","journal-title":"Neurol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1159\/000509853","article-title":"Effectiveness, Safety, and Health-Related Quality of Life of Chronic Migraine Patients Treated with Onabotulinum Toxin, A","volume":"83","author":"Beckmann","year":"2020","journal-title":"Eur. Neurol."},{"key":"ref_40","first-page":"409","article-title":"The Neck Disability Index: A study of reliability and validity","volume":"14","author":"Vernon","year":"1991","journal-title":"J. Manip. Physiol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E1038","DOI":"10.1097\/BRS.0b013e3182579795","article-title":"Development of the Italian Version of the Neck Disability Index: Cross-cultural adaptation, factor analysis, reliability, validity, and sensitivity to change","volume":"37","author":"Monticone","year":"2012","journal-title":"Spine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","article-title":"Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache- related disability","volume":"56","author":"Stewart","year":"2001","journal-title":"Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1212\/WNL.53.5.988","article-title":"An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score","volume":"53","author":"Stewart","year":"1999","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1046\/j.0333-1024.2001.00277.x","article-title":"The Migraine Disability Assessment (MIDAS) questionnaire: Translation and reliability of the Italian version","volume":"21","author":"Mosconi","year":"2001","journal-title":"Cephalalgia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/ene.14715","article-title":"Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial","volume":"28","author":"Ashina","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10194-011-0339-z","article-title":"Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: A multicenter, double-blind, randomized, placebo-controlled, parallel group study","volume":"12","author":"Sandrini","year":"2011","journal-title":"J. Headache Pain"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","article-title":"double-blind comparison of onabotulinumtoxina (BOTOX\u00ae) and topiramate (TOPAMAX\u00ae) for the prophylactic treatment of chronic migraine: A pilot study","volume":"49","author":"Mathew","year":"2009","journal-title":"Headache"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1526-4610.2007.00949.x","article-title":"Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine","volume":"48","author":"Blumenfeld","year":"2008","journal-title":"Headache"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10072-014-1741-5","article-title":"The cost effectiveness of Botox in Italian patients with chronic migraine","volume":"35","author":"Ruggeri","year":"2014","journal-title":"Neurol. Sci."},{"key":"ref_50","first-page":"196","article-title":"Acupuncture and botulinum toxin A injection in the treatment of chronic migraine: A randomized controlled study","volume":"8","author":"Naderinabi","year":"2017","journal-title":"Casp. J. Intern. Med."},{"key":"ref_51","first-page":"51","article-title":"Does the efficacy of different doses of Botulinum neurotoxin in chronic migraine change in terms of age and sex?","volume":"62","author":"Ozon","year":"2020","journal-title":"G\u00fclhane Tip Dergisi"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ornello, R., Baraldi, C., Ahmed, F., Negro, A., Miscio, A.M., Santoro, A., Alpuente, A., Russo, A., Silvestro, M., and Cevoli, S. (2022). Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph191710975"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3284446","DOI":"10.1155\/2022\/3284446","article-title":"Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review","volume":"2022","author":"Shaterian","year":"2022","journal-title":"Pain Res. Manag."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e027953","DOI":"10.1136\/bmjopen-2018-027953","article-title":"Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine","volume":"9","author":"Herd","year":"2019","journal-title":"BMJ Open"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Percent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT","volume":"86","author":"Silberstein","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1468-2982.2003.00543.x","article-title":"The family impact of migraine: Population-based studies in the USA and UK","volume":"23","author":"Lipton","year":"2003","journal-title":"Cephalalgia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)","volume":"31","author":"Blumenfeld","year":"2011","journal-title":"Cephalalgia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00702-016-1539-0","article-title":"Long-term treatment of chronic migraine with OnabotulinumtoxinA: Efficacy, quality of life and tolerability in a real-life setting","volume":"123","author":"Kollewe","year":"2016","journal-title":"J. Neural. Transm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0333102416652092","article-title":"OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program","volume":"36","author":"Lipton","year":"2016","journal-title":"Cephalalgia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1526-4610.2004.446005.x","article-title":"Impact of headache on quality of life in a general population survey in France (GRIM2000 Study)","volume":"44","author":"Duru","year":"2004","journal-title":"Headache"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s10194-021-01260-4","article-title":"Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: The REPOSE study","volume":"22","author":"Kollewe","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s10194-020-01162-x","article-title":"Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway","volume":"21","author":"Axelsson","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","article-title":"A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine","volume":"23","author":"Khanal","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-019-0976-1","article-title":"REPOSE Principal Investigators. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: The REPOSE study","volume":"20","author":"Ahmed","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2012.505","article-title":"Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: A meta-analysis","volume":"307","author":"Jackson","year":"2012","journal-title":"J. Am. Med. Assoc."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Dermitzakis, E.V., Vikelis, M., Vlachos, G.S., and Argyriou, A.A. (2022). Prospective Comparison of Longer Needle Lengths to Assess the Risk of OnabotulinumtoxinA-Associated Neck Pain in Patients with Chronic Migraine. Toxins, 14.","DOI":"10.3390\/toxins14070434"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40264-019-00824-3","article-title":"Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study","volume":"42","author":"Winner","year":"2019","journal-title":"Drug Saf."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective studies-utility and caveats","volume":"50","author":"Talari","year":"2020","journal-title":"J. R. Coll Physicians Edinb."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/14740338.2021.1907342","article-title":"Deprescribing in migraine","volume":"20","author":"Martelletti","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/14737175.2020.1821655","article-title":"Combination therapy in migraine: Asset or issue?","volume":"20","author":"Martelletti","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0304-3959(83)90126-4","article-title":"The validation of visual analogue scales as ratio scale measures for chronic and experimental pain","volume":"17","author":"Price","year":"1983","journal-title":"Pain"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six-item short-form survey for measuring headache impact: The HIT-6","volume":"12","author":"Kosinski","year":"2003","journal-title":"Qual. Life Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1023\/A:1026167214355","article-title":"study of the feasibility of Internet administration of a computerized health survey: The headache impact test (HIT)","volume":"12","author":"Bayliss","year":"2003","journal-title":"Qual. Life Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1023\/A:1026171315263","article-title":"Translating the short form Headache Impact Test (HIT-6) in 27 countries: Methodological and conceptual issues","volume":"12","author":"Gandek","year":"2003","journal-title":"Qual. Life Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/1\/29\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:48:49Z","timestamp":1760147329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/1\/29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["toxins15010029"],"URL":"https:\/\/doi.org\/10.3390\/toxins15010029","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}